KIINCE is a clinical therapeutic device to retrain the fundamentals of balance required for walking. The product’s core technology provides practice to progress patients toward producing the neuromuscular coordination required for balance. Initially targeting the identifiable stroke market, this technology is applicable to any gait therapy.

Currently in the commercialization phase, KIINCE is completing patient data collection and initial clinician evaluations leading to the first clinical placements later this year. In 2016, KIINCE will secure its first commercial sale to a gait rehabilitation center and launch a national sales and educational campaign targeting top 100 gait rehabilitation centers in the US.

With an FDA 510(k) path to market and a reachable market with identifiable comparable products, KIINCE targets rapid growth and an early strategic acquisition. To accomplish this, a round of equity financing will be offered later this year along with additional grant funding.